Form 5 - Annual statement of changes in beneficial ownership of securities:
SEC Accession No. 0000925421-19-000049
Filing Date
2019-02-14
Accepted
2019-02-14 16:02:21
Documents
1
Period of Report
2018-12-31

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT edgar.html 5  
1 PRIMARY DOCUMENT edgar.xml 5 7929
  Complete submission text file 0000925421-19-000049.txt   10093
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 5 | Act: 34 | File No.: 001-37766 | Film No.: 19605917
SIC: 2834 Pharmaceutical Preparations

Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139
Business Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 (617) 871-8000
Novartis Institutes for BioMedical Research, Inc. (Reporting) CIK: 0001673852 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 5 | Act: 34 | File No.: 001-37766 | Film No.: 19605916